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INTRODUCTION 
Over the last decade, cardiovascular diseases have become the major cause 
of mortality Worldwide. The south Asian region, one of the world’s most densely 
populated regions, comprises about 20% of the world’s population,  
The Worlds 20% of the population live in south Asian zone and the density 
of the population is very high. Being India, largest county in this area, having more 
than 3 crores of CAD patients. More than 30% of the total population lives in the 
urban areas this is expected to increase to more than 40% in the next decade. The 
incidence and prevalence steadily increasing from seven percentage in early 90s to 
ten percentage in the turn of the millennium. The rural people once thought to be 
protected from CAD are no longer true. More than half of the CV deaths occur in 
people less than 70 yrs which create a social burden on our country. 
Almost all coronary heart disease results from coronary atherosclerosis. 
Atherosclerosis is the leading cause of morbidity and mortality throughout the 
Globe. In acute coronary artery disease generally with superimposed coronary 
thrombosis. Non-atherogenic forms of coronary artery disease are less common. 
During the natural evolution of atherosclerotic plaques, especially lipid-laden 
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plaques, an abrupt and catastrophic transition can occur, characterized by plaque 
disruption. The last couple of years have witnessed a sea change in the field of 
atherosclerosis both in terms of enhanced understanding and in the availability of 
rich panoply of therapeutic options. 
Going down the memory lane of atherosclerosis we see that, 
In 70s, Atherosclerosis was considered to be a relentlessly progressive 
disease with no control whatsoever over it and arresting the progress of 
atherosclerosis or its regression was considered a myth and the idea was totally 
mooted out. 
In 80s, Things changed a little and there was silence over this issue. 
In the 90s, the answer to the above issue was perhaps “yes”. 
From the year 2000 onwards, modulation of atherosclerosis has become a 
reality and we can assess the components of atherosclerosis i.e. Lumen of the 
vessels (coronary angiography and CT- angiography, Angioscopy), Plaque 
morphology (vascular MRI, IVUS, OCT), Inflammation (intravascular 
Thermography, FDG, PET imaging, Biochemical markers) over the last fifteen 
years. However, a prominent role for inflammation in the pathogenesis of 
atherosclerosis has been established (Libby et al., 2002), the concept that 
inflammation governs atherosclerosis and its complication has provided a new 
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unifying hypothesis of the link between risk factors and the cellular and molecular 
alterations that underlie this disease (Libby and rider, 2006).the hallmark of the 
early atherosclerotic lesions is the cholesterol ester-laden macrophage foam cell 
(ross, 1995). Progressive free cholesterol loading of lesional macrophages leads to 
a series of Phospholipid-related adaptive responses. These adaptive responses 
eventually fail, leading to macrophage death which further can lead to lesional 
necrosis, release of cellular proteases, inflammatory cytokines, and adipokines and 
prothrombotic molecules. These could contribute to plaque instability, plaque 
rupture, and acute thrombotic vascular occlusion (Tabas, 1997). One such 
inflammatory markers, serum IL-6 and TNF alpha levels which has come under 
increasing examination over past ten years or genetics and in particular, the genes 
involved in the regulation of serum IL-6 and TNF alpha levels within the body. 
Hence, the present study focuses on the role of serum IL-6 and TNF alpha levels 
and their association with CVD.  
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AIM OF THE STUDY 
 
1. To determine the relationship of serum TNF alpha values and Interleukin 6 with 
coronary artery disease. 
 
2. To determine the relationship of serum TNF alpha and serum Interleukin 6 
values with angiographic severity of coronary artery disease 
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Review of literature 
 
The immune system: cytokines and their function 
The effective immunity is due to the interaction of multiple cell types 
including myeloid cells and lymphocytes. The complex interactions among these 
cells are in part mediated by cytokines. Cytokines are relatively small regulatory 
proteins that are secreted from cells of innate and adaptive immunity as well as 
various other cell types in response to a number of stimuli. On one hand, a 
subgroup of these proteins stimulate the growth and differentiation of various cells 
during immune homeostasis, while on the other hand, cytokines facilitate the 
activation and differentiation of effector cells both during the natural and acquired 
phases of immunity against foreign antigens such as bacteria, viruses or self-
antigens. Binding of cytokines to specific receptors on the membrane of target cells 
leads to the activation of diverse signal-transduction pathways which ultimately 
lead to altered gene expression. 
In recent years cytokines and their receptors have become important targets for 
specific antagonists in various immune and inflammatory diseases. One of these 
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cytokines that is considered as such a target, due to its pro-inflammatory functions 
is the cytokine Interleukin-6.  It is involved in the regulation of immunity, 
hematopoiesis, bone metabolism and inflammatory state. The increase in 
Interleukin-6 seen implicated in the pathology of connective tissue and 
autoimmune conditions and also in coronary artery disease, RA, Crohn’s, 
Castleman’s disease and JRA. So IL-6 pathway modulation has become an 
interesting target for the therapy of above conditions. 
 
The discovery of Interleukin-6 
The history of nomenclature reflects the diverse biological functions of this 
cytokine: Interleukin was initially found to be T cell-derived factor which induces 
B-cell to produce antibodies. It was first termed B cell stimulatory factor-2. 
Complementary DNA was later cloned.  
 
Interleukin 6 expression and structure 
The human Interleukin 6 gene contains four introns and four exons and maps 
to chromosome 7p21. Interleukin 6 has molecular weight ranging from 21 – 28 
kilo Dalton. Murine IL 6 and Human IL 6 have 65% similarity at their DNA level. 
IL-6 is not constitutively expressed in the human body, but is induced by a large 
number of multiple stimuli including bacterial and viral infections, microbial 
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components such as lipopolysaccharide (LPS) and different cytokines (11). IL-1β, 
TNF-α and IFN-γ  are potent inducers of  Interleukin 6 expression in various cells 
like T cell, B cell, various tumor cells, monocyte, endothelial cell and fibroblasts. 
 
Interleukin-6 promoter 
IL6 gene is regulated by a series of transcription factors. Depending on the 
extracellular stimuli and cell type their interactions differ. So far, several functional 
cis-regulatory elements in the human IL-6 promoter have been identified, including 
nuclear factor-kappa B (NF-κB) (position -62 to –49 relative to the translational 
start codon), nuclear factor-IL6 (NF-IL6) (-144 to -132), cAMP response element 
binding protein (CREB) (-152 to -145) and activator protein-1 binding sites. 
The Rel family of transcription factors includes NF-κB. IκBs (Inhibitors of 
κB) inhibit NF-κB in resting state. Upon activation of cells by diverse stimuli, IκBs 
become phosphorylated and are rapidly degraded. The degraded IκBs can no 
longer bind to NF-κB which is therefore released. It translocates into the nucleus 
which binds specific DNA recognition site, contributing transcriptional activation 
of multiple genes. 
A low level of NF-IL6 is seen in primary cells. TNF-α, IL-1β or LPS 
strongly stimulate NF-IL6 expression. In contrast, NF-IL6 is constitutively 
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expressed in many cell lines. Phosphorylation of NF-IL6 has been shown to 
increase its transcriptional activity. 
Studies in various cell types have shown that induction of IL-6 gene transcription 
is complex and involves the coordinated regulation of factors that associate with 
the evolutionary conserved NF-κB, NF-IL6 and AP-1 sites in the mouse and 
human IL-6 promoter. 
 
Cellular signaling and regulation of Interleukin-6 
Receptors of IL 6 are unique. The IL-6 receptor has a 80 kilo Dalton protein which 
binds to interleukin 6 and another 130 kilo Dalton protein which functions as a 
transducer of signals. 
The 80 kilo Dalton IL-6 receptor can exist as soluble or transmembrane 
form.  
Transmembrane type 
It has got intracytoplasmic - 82 aminoacids 
It lacks tyrosine-kinase domains  
No enzymatic role in IL-6 signaling 
When IL-6 binds to its membranous receptor, it brings both intracellular 
segments in two IL-6R chains with close proximity, thus permitting the attachment 
of intracellular IL-6R segments with 130 kilo Dalton g-protein. This is found to 
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induce formation of a multimer consisting of two Interleukin 6 bound to the 
intracytoplasmatic segments of the two IL-6R proteins. 
On the other hand, the soluble form of IL-6R, which is produced by cleavage 
of the membranous IL-6R or by alternative splicing, can bind IL-6. Two IL-6 
molecules, two soluble IL-6R proteins and two gp130 proteins bind together to 
form a complex. This is able to transmit signals via trans-signaling. Gp130 protein 
dimerization induces activation of JAK tyrosine protein kinase family. The JAK 
kinase family consists four non-receptor tyrosine kinase members. They are Tyk2, 
JAK1, JAK, and JAK3 which selectively phosphor late the signal transducer and 
activator of transcription (STAT) proteins thus leading to their activation. STAT3 
phosphorylation is induced by JAKs by translocating inside nucleus in its 
phosphorylated form and induces gene expression. 
Overproduction of IL-6 leads to inflammation and disease; therefore this 
cytokine must be regulated to control the duration and magnitude of IL-6 response. 
A negative feed-back loop regulates the IL-6 signaling system via activation of 
SOCS (suppressors of cytokine signaling) and PIAS (Inhibitors of activated 
STATs).  Phosphorylated STAT3 translocates inside nucleus which induces 
expression of SOCS3, which binds to JAKs and thus suppresses transduction of GP 
130 protein.  STAT proteins are negatively regulated by PIAS. In the case of IL-6 
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signaling, PIAS3 associates specifically with activated STAT3 blocking further 
gene transcription. 
 
Interleukin-6 and its Biological effects 
Initial description of IL-6 was a B-cell differentiation factor. Further studies 
showed that production of Immunoglubulins from B cells is enhanced by 
Interleukin 6.   
Exposure to anti-IL-6 antibody to B-cell causes decreased production of 
immunoglobulin but does not affects their proliferation. IL-6 is thought to be 
important factor for production of antibodies by activated B-cell, unaffecting their 
proliferation. Later on   IL 6 was found to have diverse functions on multiple cell 
types. T cell activation by IL 6 induces production of IL 2 and expression of its 
receptor. Moreover cytotoxic T-cells formation is brought about by conjugation of 
IL 6 with IL 2. Furthermore, Interleukin 6 acts as a terminal differentiation factor 
for macrophages. 
In response to inflammatory signals, Liver cells trigger acute phase response 
by reduced production of  Albumin and increased production of  Haptoglobulin, 
CRP, Serum Amyloid A, Alpha 1 antitypsin and Fibrinogen, which is triggered by 
IL-6 in response to tissue injury. This is confirmed by various studies in Human 
hepatocytes. IL 6 considered as a major inflammatory  mediator triggering  acute 
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phase response. Along with IL 3, it also induces production of multilineage 
precursor cell types. Soluble Interleukin 6 receptor is involved in bone metabolism 
by triggering osteoclast differentiation. Furthermore, IL-6 acts on the 
differentiation of megakaryocytes to produce platelets and has been shown to 
support the survival of cultured cholinergic neurons. 
 
Process of early Atheroscelerosis  
 
Process of early Atheroscelerosis  
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Hence the following study designed to find the correlation between Serum 
TNF alpha & Interleukin 6 levels in correlation with coronary artery disease 
severity.    
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MATERIALS AND METHODS 
 
METHODOLOGY 
                       This chapter deals with the research approach and design, setting of 
the study , variables , population, sample size, sampling technique, Sample 
selection criteria, development and description of the tool, scoring procedure, 
procedure for data collection and plan for data analysis. 
 
RESEARCH APPROACH AND DESIGN 
                       The approach chosen for the study is cross sectional analysis 
correlating severity of coronary angiography with increased serum values of TNF 
alpha, Interleukin 6 in CAD patients. Fasting Serum samples of TNF alpha, IL 6, 
Lipids, Blood glucose were taken on the day of coronary angiography. Patient’s 
past medical history including any drug intake was obtained and clinical 
examination was done.    
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SETTING OF THE STUDY 
                   The study was carried out at the Madras Medical College and Hospital, 
in Chennai. Madras Medical College is Government Medical College attached 
Hospital, which runs Inpatient and outpatient services. 
 
VARIABLES  
                The variables in the study are the demographic variables, BMI, Blood 
pressure recordings, Fasting Sugar levels, Lipid Profile, serum IL-6 and TNF alpha 
levels and Coronary Angiography. The severity of coronary artery disease 
measured with standardized coronary angiographic technique (QUA)-Gensini 
score.   
 
POPULATION 
                This study included 122 Adults undergoing diagnostic CAG at Madras 
Medical College and Hospital. Coronary Angiogram was done in the Cath lab of 
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the department of Cardiology, Madras Medical College and Hospital. Control 
group persons without coronary artery disease are selected for serum IL-6 and TNF 
alpha levels measurement without coronary angiogram.  
SAMPLING TECHNIQUE  
                          Non probability convenient sampling technique was used for 
sample selection based on the inclusive and exclusive criteria.  
 
INCLUSION CRITERIA 
All patients of ischemic heart diseases admitted for CAG in department of 
cardiology, Madras Medical College Hospital. 
 
EXCLUSION CRITERIA 
1. Patients with past history of Coronary Artery Bypass Grafting. 
2. Patients who had undergone PTCA. 
3. Patients with Valvular heart disease. 
4. Patients with Hepatic dysfunction. 
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5. Patients with a major non-cardiovascular disease. 
6. Patients with Collagen vascular diseases. 
7. Any Systemic Infection. 
8. Patients with history of coronary angiography in the recent past. 
9. unwilling to give consent. 
Using the above criteria those with uncomplicated Acute STEMI were  lysed 
using streptokinase, underwent coronary angiography in 2 to 4 weeks. Control 
patients group with Acute STEMI with post infarction angina, unstable angina, 
NSTEMI and chronic stable angina were subjected for coronary angiography. 
122 cases were elected for inclusion in the study based on clinical 
assessment and laboratory screening. An informed consent was obtained from each 
patient before inclusion in the study. Patient’s age, gender, co-morbid conditions, 
smoking history, BMI, Blood pressure recordings, Weight, Height, Waist: Hip 
Ratio, heart rate and medication history were noted. Fasting Serum concentrations 
of glucose, creatinine, urea and lipid profile were measured using standard 
laboratory procedures. 
Systemic Hypertension defined as systolic BP > 140 mmHg and diastolic BP 
> 90 mm Hg in various postures. Diabetes mellitus being defined by fasting sugar 
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> 126 mg/dl on two occasions, or  patients already on OHA or on insulin. 
Hypercholesterolemia  defined by total cholesterol > 200 mg/dl or LDL-C > 
130mg/dl, or as patients already on Statin treatment. 
Fasting blood samples of the participants were collected at the day of 
angiography and sent for analysis of serum IL-6 and TNF alpha levels. 
 
DETERMINATION OF Interleukin 6 and TNF alpha 
Serum Interleukin 6 and TNF alpha levels are quantitatively determined on 
patient’s serum by enzyme immunoassay method.  
 
DETERMINATION OF IL-6 
IL-6 was quantitatively determined in patient’s serum by enzyme linked 
immunosorbent assay method. The assay employs an antibody specific for human 
IL-6 coated on a 96-well plate. Standards, samples and biotinylated anti-human IL-
6 are pipetted into the wells and by the biotinylated IL-6 specific detection 
antibody. After washing away unbound biotinylated antibody, HRP-conjugated 
streptavidin is pipetted to the wells. The wells are again washed. Following this 
second wash step, TMB substrate solution is added to the wells, resulting in color 
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development proportional to the amount of IL-6 bound. The stop solution changes 
the colour from blue to yellow, and the intensity of the color is measured at 450nm. 
 
ECHOCARDIOGRAPHIC DATA 
  Two dimensional and M-mode measurements were obtained with patients in 
left lateral position using a Philips HD7 phased array system equipped with tissue 
Doppler and harmonic imaging technology with Doppler frequency of 2.5 to 3.8 
MHZ. With measurement of LV EDD in diastole and LV ESD in systole, LV EF 
was measured by Teicholtz method. 
 
CORONARY ANGIOGRAPHIC DATA 
Coronary angiogram was done in the Toshiba Cath lab in our hospital. CAG 
was done through Radial or femoral approach. 
Coronary angiograms were done through radial or femoral approach using 
modified Seldinger technique after getting patients and patient’s relatives consent. 
CAG was done with minimum 4 views of LCA and 2 views of RCA. Low osmolar 
nonionic contrast agent was used.  Coronary artery stenosis was evaluated by use 
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of multiple projections quantitative analysis was done with medical imaging 
system CMS analysis software. 
 
 
DETERMINATION OF CAD SEVERITY 
   
 Following coronary angiogram, the degree of narrowing was assessed by 
taking into account the maximum narrowing of each stenotic lesion in at least two 
orthogonal views. The severity of CAD was evaluated by the 0 to3 vessel disease 
score, Gensini and ACC/AHA scores. 
 
In the clinical 0 to 3 vessel disease scoring system arteries were as being 
involved if more than 50% luminal diameter narrowing occurred, and the patients 
were defined as having 0-,1-,2-,3 vessel disease according to the number of  
vessels involved.  
The 3 coronary scoring systems are described   
 
25 
 
LEAMAN SCORE 
Coronary artery score equals the sum of all segment scores (each segment 
score equals coronary segment value multiplied by a weighting factor). Weighting  
factors assigned to the specific percentage luminal diameter  reduction of the 
coronary artery segment are 5 for 100%, 3  for 90-99%,and 1 for70-89%.here we 
are not using  this scoring system .we are using commonly using scoring system 
 
GENSINI SCORE 
The Gensini scoring system is a valuable aid to estimate the severity of CAD 
according to angiographic findings. The calculation is based on the evaluation of 
number of stenotic segments along with their respective degrees of luminal 
narrowing and localization within the coronary tree. 
 
The above scoring system is to grade severity of CAD in CAG  
Score 1 – 1 - 25% 
Score 2 – 26 - 50% 
Score 4 – 51 - 75% 
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Score 8 – 76 - 90% 
Score 16 – 91- 99% 
Score 32 – 100 % Block 
  
After calculating the score it is multiplied by location of the occluded plaque 
to corresponding artery 
5 – LMCA 
2.5 – LAD before D1 & S1, LCX 
1.5 – Mid LAD 
1    – Distal LAD / Distal LCX / Entire RCA 
0.5 – D2/ PLB 
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The above scoring system takes into consideration of the following factors in 
calculating the score – location of the plaque and in which artery the plaque 
present mainly in left system or the right system. 
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American College of Cardiology / American Heart Association scoring system  
CAD scoring system calculated by adding scores from all segments of 
coronary artery. The scoring given for each lesion based on luminal narrowing. 
Score 0 – Less than 10% 
Score 1 – 10 to 49% 
Score 2 – 50 to 74% 
Score 3 – 75 to 89% 
Score 4 – 90 to 100%  
The branches of LAD or LCX like Diagonals, OMs, Septals and distal LAD 
with adequate diameter greater than any other branches have been added to the 
scoring value. 
Two Cardiologists calculated the Coronary stenosis severity approved by 
Professor of Cardiology, Madras Medical College and Hospital. 
In contrary to the other scoring systems like Gensini & Leaman, the above 
scoring pattern give equal weightage to all the segments involved even though they 
vary in their size and blood flow. 
 
29 
 
DEVELOPMENT AND DESCRIPTION OF THE TOOL 
 
With the researcher’s personal and professional experience and after 
extensive review of literature and discussion with experts, a structured interview 
schedule was developed for data collection of the study.  For convenience of data 
collection procedure the tool was translated into Tamil.  
 
Structured Interview schedule  
 
This consist of 2 sections 
Section –I 
Demographic data regarding patients age, sex. 
Section –II 
Interview schedule to assess the information need of study. 
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PROCEDURE FOR DATA COLLECTION  
Data collection for the study was done at Department of Cardiology, Madras 
Medical College & Hospital Chennai, after obtaining necessary permission from 
the authorities. The data was collected after a brief introduction about self and the 
study’s purpose and after obtaining the written consent of the significant family 
members of Cardiac Patients. 
 
Data encoding and data analysis. 
             The collected data were coded in Spreadsheet (Excel) format. Specific 
codes were developed that were compatible with the subsequent statistical analysis. 
The coded data were then analyzed with Windows SPSS software (Version 17.0). 
The results of the analysis were tabulated and inference made from these 
tabulations. 
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STATISTICAL ANALYSIS 
 
The patient data is analyzed by standard statistical methods. Variables are depicted 
as Mean ± S D, Frequencies, Percentages.  
 
The student t test and another method of Analysis of Variance have been used to 
compare continuous variables. 
 
The correlation was done by multiple linear regression and linear regression. 
 
P values calculated and regarded significant when the value is less than 0.05 
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RESULTS AND DATA ANALYSIS 
        
 This chapter deals with the analysis and interpretations of data collected 
from 122 significant family members of cardio patients at Dept. of Cardiology, 
Madras Medical College and Hospital, Chennai to assess the informational need on 
the study. Data collected from 103 normal persons without coronary angiogram 
from medical camps. 
Table-1 
Age distribution of the Sample  
Age Group 
Male Female Total 
No of  
Patient % 
No of 
Patients % 
No of 
Patients 
% 
< 30 1 00.99 1 04.76 2 01.63 
31- 40 15 14.85 3 14.29 18 14.75 
41 -50 37 36.63 8 38.10 45 36.88 
51 – 60 38 37.62 8 38.10 46 37.70 
61 – 70 10 09.90 1 04.76 11 9.01 
Total 101 100 21 100 122 100 
Mean ± S d 50.14 ± 9.00 48.57 ± 9.84 49.87 ± 9.13 
 t=0.71 df=120 Not Significant  
 
Patients were distributed across the age group of 30 to 70 years. Mean age of 
the patients was 49.87 ± 9.13 years. (Male=50.14 ± 9.00 & Female = 48.57 ± 
9.84). Most patients (n=46) were in the age group of 51-60 years. Youngest patient 
 was 23 years old and oldest was 67 years. There is no significant difference was 
found between male and female age.
Table-2 
Body Mass Index  
Body Mass 
Index 
Male
No of  
Patient 
Normal 48 47.52
Under 
Weight 6 
Over Weight 23 22.77
Obese 22 21.78
Morbid 
Obese 2 
Total 101 
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35
40
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 Female Total
% No of Patients % 
No of 
Patients 
 4 19.05 52 
5.94 0 0 6 
 8 38.10 31 
 9 42.85 31 
1.98 0 0 2 
100 21 100 122 
41 - 50 Yrs 51 - 60 Yrs 61 - 70 Yrs
 
 
% 
42.62 
4.92 
25.41 
25.41 
1.64 
100 
Male
Female
  
Distribution of Body mass index of study subjects revealed that majority of 
them52 (42.62 %) have Normal; 6 (4.92 %) have 
Morbid Obese; 31 (25.41 %) Over weight 
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underweight; 2 (1.64 %) had 
and 31 (25.41 %) had Obese.
Over weight Obese Morbidly 
Obese
 
 
Male
Female
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Table-3 
Body Mass Index  
Characteristics 
Male 
patients 
Female 
patients Total Significant 
 Mean ±      
S D 
Mean ±     
S D 
Mean ±     
S D 
Weight (Kg) 64.62 ± 10.27 
61.00 ± 
9.43 
64.02 
±10.19 
t=1.46 
df=119 
NS 
Height (Cm) 165.28 ±  8.22 
152.20 ± 
8.08 
163.12 ± 
9.51 
t=6.52 
df=119 
P<0.001 
Body Mass Index 
(Kg/m2) 
23.71 ±  
3.63 
25.55 ± 
3.15 
24.02 ± 
3.61 
t=2.11 
df=119 
P<0.04 
S D= Standard Deviation   NS – Not Significant  
 
The above table reveals that the association between body mass index and 
gender involvement of the sample. Mean weight total was 64.02 ±10.19 and the 
mean value in males was 64.62 ± 10.27 and in females was 61.00 ± 9.43. T-value 
reveals that there is no significant difference between weight and gender.  
Comparison between gender and Height of the patients. T-value reveals that 
there was a statistically significant difference between male patients and female 
patients. 
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The mean score of male, female and total were 23.71 ± 3.63, 25.55 ± 3.15 
and 24.02 ± 3.61. Difference between BMI scores of males and female is 
significant at P<0.04 
 
TABLE-4 
Control group 102 persons (Mean ± S D) 
 Number BMI P value 
Normal 21 21.5629+1.3 
 
P<0.030 
Overweight 45 24.7096+1.2 
 
P<.003 
Obese 36 31.6586+3.4 P<.005 
 
 
 Distribution of Body mass index of study subjects revealed that majority of 
them42 (41.17 %) have overweight; 21 (20.58 %) had normal; 36 (35.29 %) had 
Obese. 
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Table-5 
Characteristics 
Male 
patients 
Female 
patients Total Significant 
 Mean ±      
S D 
Mean ±     
S D 
Mean ±     S 
D 
Waist (inch) 36.53 ±  3.58 
35.75 ± 
4.08 
36.41 ±  
3.66 
t=0.88 
df=119 
NS 
Hip (Cm) 37.95 ±  3.11 
39.80 ± 
3.97 
38.41 ±  
3.33 
t=2.31 
df=119 
P<0.02 
S D= Standard Deviation   NS – Not Significant  
       
The mean Waist of the sample was 36.41 ± 3.66 the mean waist not differed 
between Genders.  Males had 36.53 ± 3.58 and female had 35.75 ± 4.08 
The mean Hip score was significantly differed between male (37.95 ± 3.11) and 
female (39.80 ± 3.97) at P< 0.02. 
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Table-6 
Blood Pressure  
Characteristics 
Male 
patients 
Female 
patients Total Significant 
 Mean ±       
S D 
Mean ±       
S D 
Mean ±        
S D 
Systolic Blood 
Pressure (mmHg) 
134.55 
±23.52 
137.62 ± 
20.23 135.08±22.94 
t=0.56 
df=120 
NS 
Diastolic Blood 
Pressure (mmHg) 
90.29 ± 
14.72 
91.90 ± 
15.04 89.90±16.48 
t=0.46 
df=120 
NS 
 
The mean SBP of the sample was 135.08±22.94. The mean SBP score not 
differed significantly between males and females. The mean DBP was found to be 
89.90±16.48, but did not differ significantly between males (90.29 ± 14.72) and 
females (91.90 ± 15.04).  
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Table-7 
Laboratory Data 
Characteristics 
Male 
patients 
Female 
patients Total Significant 
 Mean ±     
S D 
Mean ±           
S D 
Mean ±       
S D 
Fasting Blood Sugar 
(mg/dl) 
149.90 
±63.79 219.86±106.58 168.94±77.10 
t=4.01 
df=120 
P<0.001 
Cholesterol (mg/dl) 221.84 ± 59.61 223.70 ± 64.37 222.15±60.15 
t=0.13 
df=118 
NS 
Triglycerides(mg/dl) 169.57 ± 69.58 161.05 ±50.01 168.15±66.61 
t=0.52 
df=118 
NS 
LDL 143.32 ± 47.25 145.45 ±50.75 143.68±47.68 
t=0.18 
df=118 
NS 
HDL 41.93 ±  8.80 42.20 ± 11.31 41.98± 6.21 
t=0.12 
df=118 
NS 
VLDL 32.91 ± 13.14 32.15 ±  9.68 32.78±12.60 
t=0.25 
df=118 
NS 
S D= Standard Deviation   NS – Not Significant  
The above table reveals that association between level of Laboratory score 
and Gender to the patient. The Mean score on Fasting Blood Sugar mean of male 
was 149.90 ±63.79 and female was 219.86±106.58. T-value reveals statistically 
significant difference. 
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Though Females had meant level of Cholesterol of 223.70 ± 64.37 which is 
more than that the male’s mean Cholesterol of 221.84 ± 59.61. t-value reveals that 
there is no significant difference between sex patient and cholesterol level. 
The mean score on Triglycerides (mg/dl) of male is 169.57 ± 69.58 and 
female is 161.05 ±50.01. The males had higher score than females but the 
difference is not statistically significant.     
The mean score on LDL female is 145.45 ±50.75and male is 143.32 ± 47.25.  
Females had little high score than males but the difference is not statistically 
significant.     
Females had mean level of HDL of 42.20 ± 11.31 which is more than that 
the male’s mean HDL score of   41.93 ± 8.80. t-value reveals that there is no 
significant difference between sex patient and cholesterol level. 
The mean score on VLDL male is 32.91 ± 13.14 and female is 32.15 ± 9.68. 
The difference is not statistically significant.  
The distribution of coronary artery system among 122 patients are 9.8% 
(12patients) are co-dominant system, 15.5 %(19 patients) are left-dominant system, 
and 74.59%(91 patients) are right dominant system.63 patients are thrombolysed. 
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Table-8 
 
Coronary Angiography 
Coronary 
Angiography 
Male Female Total 
No of  
Patient % 
No of 
Patients % 
No of 
Patients % 
Normal 17 16.83 4 20.00 21 17.36 
SVD 30 29.71 4 20.00 34 28.10 
DVD 31 30.69 5 25.00 36 29.75 
TVD 23 22.77 7 35.00 30 24.79 
Total 101 100 20 100 121 100 
 
Chi square=1.85 df=3 Not Significant 49.87 ± 9.13 
 
The above table reveals that association between the level of Coronary 
information and gender status of significant patients. Among the patients 36 (29.75 
%) who had Double Vessel Disease; 34 (28.10 %) who had Single Vessel Disease; 
30 (24.79 %) who had Triple Vessel Disease and 21 (17.36 %) who had Normal.  
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The Chi-square value reveals that there is no significant association between 
Coronary Disease status and the Gender.       
 
Table-9 
Diagnosis 
0
5
10
15
20
25
30
35
Normal SVD DVD TVD
Male
Female
 Group 
Male 
No of  
Patient 
CAD 48 47.52
AMI 53 52.48
Total 101 100
 
Chi square= 5.73   df=1  p< 0.02             
 
 
The total sample 122 was used for this study. Males comprised 101 
(82.79%) and female 21 (17.21%) of the total. Majority 64 (52.46 %) of the sample 
0
10
20
30
40
50
60
CAD
48
16
43 
Female Total
% No of Patients % 
No of 
Patients 
 16 76.19 64 
 5 23.81 58 
 21 100 122 
Significant  
AMI
53
5
Male
Female
 
% 
52.46 
47.54 
100 
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were CAD and remaining 58 (47.54 %) were Non CAD. The distribution between 
sex of the CAD and Non CAD were statistically significantly differs p < 0.002. 
 
Table-10 
Co Morbid conditions 
Group 
Male Female Total 
No of  
Patient % 
No of 
Patients % 
No of 
Patients % 
None 57 56.40 10 47.60 67 54.90 
Diabetic 9 8.90 0 0 9 7.40 
Hypertension 9 8.90 1 4.80 10 8.20 
Previous CAD 23 22.80 4 19.00 27 22.10 
DM/HT/PREVIOUS 
CAD 3 3.0 6 28.60 9 7.40 
Total 101 100 21 100 122 100 
 
Chi square= 18.40   df=4  p< 0.001             
Significant   
 
 
In this 122 patients   57(56.40%) patients were no co-morbid diseases, 
Diabetes mellitus 9 (8.90%)patients, Hypertension   9 (8.90%)patients ,previous 
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infarction 23(22.80%)patients, Both DM/HT/Previous Myocardial infarction3(3%) 
patients. Majority 64 (52.46 %) of the sample were CAD and re 58 (47.54 %) were 
Non CAD. The distribution of diseases in this group was statistically significantly 
the p value is p < 0.001. 
 
Table-11 
Diagnosis  
Characteristics 
Male patients Female patients Total Significant 
 
Mean ± SD Mean ± S D Mean ± S D 
Gensini  Score 25.67 ± 22.99 36.43 ± 31.82 27.54 ± 24.94 
t=1.81 df=119 
NS 
ACC/AHA 6.41 ±   4.89 6.67 ±   5.51 6.45± 4.98 t=0.21 df=119 NS 
S D= Standard Deviation   NS – Not Significant  
 
The table reveals that the association between Gender and Gensini & 
ACC/AHA score. The females had men level of Gensini score of 36.43 ± 31.82 
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which is more than the male’s Gensini Score of 25.67 ± 22.99. There is no 
significant difference between Gender and Gensini score of the patient.  
 
The mean score on ACC/AHA of male is 6.41 ± 4.89 and female is 6.67 ± 
5.51. The difference is not statistically significant.   
Table-16 
Coronary Angiographic Gensini score vs. significant obstructive number of 
vessels 
Variables 
Coronary Angiograpic                                  
vessel pattern 
Mean ± SD Significant 
Gensini   Normal 
Single Vessel Disease 
Double Vessel Disease 
Triple Vessel Disease 
Total 
0.70 ±  2.70 
19.81 ± 16.01 
36.67 ±  23.23 
44.15 ±  25.36 
27.76 ±  24.91 
 
F=23.22 
p< 0.001 
   
 
The Gensini score in normal vessel is 0.70 (0), in single vessel disease is 
19.81+16.01, doube vessel disease is 36.67 ± 23, and triple vessel disease is 44.15 
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± 25.36 .there is significant difference .The F=23.22, p< 0.001 .it is statistically 
significant.            
 
Table-18 
Gensini score vs. significant obstructive Coronary artery  
Characteristics 
Normal 
Significant 
obstructive 
coronary artery 
disease 
Total 
Significant 
(normal Vs 
abnormal) Mean ± 
SD 
Mean ± SD Mean ± SD 
Gensini score 
0.70 ± 
2.70 
3318 ± 23.81 
27.53 ±  
24.94 
t=6.07 
df=119 
p< 0.001 
 
The above table shows statistically significant difference between normal coronary 
artery and significant obstructive coronary artery disease. 
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Table-19 
Patient Characteristics 
  
Diagnosis N Mean Std. Deviation 
Std. Error 
Mean 
BMI CAD 63 24.45 3.57 .44 
NON CAD 58 23.54 3.61 .47 
WHO RATIO CAD 62 .9629 .20221 .02568 
NON CAD 57 .9760 .16356 .02166 
IL6 CAD 64 27.1578 7.32885 .91611 
NON CAD 58 25.7310 7.61870 1.00038 
CRP CAD 64 6.5688 1.71704 .21463 
NON CAD 58 6.8017 4.68490 .61516 
IMPRESSION CAD 63 1.75 1.047 .132 
NON CAD 58 1.48 1.030 .135 
GENSINI CAD 64 27.4453 23.77125 2.97141 
NON CAD 57 27.6404 26.39750 3.49643 
ACC_AHA CAD 64 6.6719 5.36317 .67040 
NON CAD 57 6.2105 4.53847 .60114 
 
 
The above table illustrates the patient characteristics between those having CAD 
and not having CAD. The Mean level of IL 6 in CAD patients is 27.15 nag/ml with 
standard deviation of 7.32. The non CAD patients have a mean IL 6 level of 25.73 
nag/ml.  
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Table-20: Independent samples t-test 
 
  
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 
  
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference   
BMI 0.04 0.85 1.39 119.00 0.17 0.91 0.65 
WHO RATIO 0.93 0.34 -0.39 117.00 0.70 -0.01 0.03 
IL6 0.00 0.98 1.05 120.00 0.29 1.43 1.35 
CRP 3.49 0.06 -0.37 120.00 0.71 -0.23 0.63 
GENSINI 0.27 0.61 -0.04 119.00 0.97 -0.20 4.56 
ACC_AHA 0.53 0.47 0.51 119.00 0.61 0.46 0.91 
 
Even though the mean level of IL 6 in non CAD patients is lower than that 
of CAD patients, the difference was not statistically significant (p value= 0.98) as 
depicted in the table no.20. 
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Table No-21: TNF alpha levels in relation to CAD 
 
TNF 
alpha 
levels 
(pg/ml) 
N Mean Std. Deviation 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
Normal 14 43.86 14.85 3.97 35.28 52.43 16.00 72.00 
SVD 22 40.37 25.53 5.44 29.05 51.69 14.00 114.00 
DVD 21 60.29 97.37 21.25 15.97 104.61 20.00 480.00 
TVD 20 47.68 53.74 12.02 22.53 72.83 4.00 244.00 
Total 77 48.34 59.13 6.74 34.91 61.76 4.00 480.00 
 
The Mean TNF alpha level in normal individuals is 43.86 pg/ml in our study.  The 
CAD patients with single vessel disease have mean level of 40.37 pg/ml is not 
statistically significant. The increased level of TNF alpha have been found in 
double vessel and triple vessel CAD which is not statistically significant. Further 
larger studies are needed to confirm any association between them. 
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Table-22: ANOVA for BMI 
 
 
    
Sum of 
Squares df 
Mean 
Square F Sig. 
IL6 Between 
Groups 1776.873 3 592.291 14.041 .000 
Within 
Groups 4977.466 118 42.182     
Total 6754.339 121       
CRP Between 
Groups 61.870 3 20.623 1.768 .157 
Within 
Groups 1376.569 118 11.666     
Total 1438.439 121       
 
The Correlation between Body mass index and Interleukin 6 level has been 
studied using ANOVA. There is statistically significant difference found between 
BMI groups and IL 6 levels in blood.  
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Table-23: ANOVA for CAD – Number of vessels involved 
 
    
Sum of 
Squares df 
Mean 
Square F Sig. 
IL6 Between 
Groups 59.018 3 19.673 .344 .793 
Within 
Groups 6686.122 117 57.146     
Total 6745.140 120       
CRP Between 
Groups 18.742 3 6.247 .516 .672 
Within 
Groups 1417.181 117 12.113     
Total 1435.923 120       
 
The above table indicates that there is no statistically significant difference 
between the patients who had normal coronaries or single vessel CAD or double 
vessel CAD or Triple vessel CAD with respect to the level of IL 6 or CRP in the 
blood. 
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DISCUSSION 
 
This chapter deals with the detailed discussion on the findings of the study 
interpreted from the statistical analysis. The finding are discussed in relation to the 
objectives, need for the study and the related literature of the study.  
TNF alpha  and  Interleukin 6 are one of the factor that plays a pivotal role 
connecting common forms of obesity and cardiovascular disease (Zhang et 
al.,1994).Comparison between Body mass index and TNF alpha  and  Interleukin 6 
both control group and diseased group shows positive correlation. A notable 
finding is that serum TNF alpha and Interleukin 6 increases with the increase in 
BMI. In the case of control group there is an increase in TNF alpha and Interleukin 
6 values as a function of MI. The values obtained for TNF alpha and Interleukin 6 
is interestingly found to higher in CVD group when compared to control group in 
all categories. However the difference in TNF alpha and Interleukin 6 values 
obtained for CVD and control group is much pronounced in normal BMI when 
compared to that of obese subjects. This is a clear indication of the correlation 
between Interleukin 6 values and increased BMI irrespective of the disease 
condition. 
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TNF alpha  and  Interleukin 6 values are expected to be higher in thin 
subjects and lesser in obese subjects since it is known to correlate with the energy 
expenditure. However the computed values of TNF alpha and Interleukin 6 are 
much higher in obese subjects and less in thin subjects. Thus the amount of 
circulating TNF alpha  and  Interleukin 6 might be higher in obese subjects when 
compared to thin subjects and TNF alpha  and  Interleukin 6 might play a paracrine 
role in addition to endocrine role played in humans. The increased in TNF alpha 
and Interleukin 6 values in CVD subjects when compared to that of normal 
subjects clearly suggests that TNF alpha and Interleukin 6 acts as a 
proinflammatory cytokine. 
  This the first study to show that higher serum TNF alpha and Interleukin 6 
level was associated with more severe coronary atherosclerosis confirmed by 
angiographic measurement with Gemini’s score and ACC/AHA score. 
Various studies show that there is both positive and negative correlation 
between serum TNF alpha and Interleukin 6 and clinical atherosclerosis. Soderberg 
et al found a positive association between plasma TNF alpha and Interleukin 6 
level and first myocardial infarction. V Jacob Jose et al suggest that serum TNF 
alpha  and  Interleukin 6 level is elevated in patients with first acute myocardial 
infarction (Indian Heart J 2005; 57:39-43).Robert wolk et al suggest that TNF 
alpha  and  Interleukin 6  level in angiographically proven CAD patients had 
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prognostic significance. Tamer et al found that TNF alpha and Interleukin 6 levels 
were higher in myocardial infarction patients. However, plasma TNF alpha and 
Interleukin 6 levels were not associated with CV disease in the Quebec 
Cardiovascular study. 
In our study high serum TNF alpha and Interleukin 6 level significantly 
present in coronary artery disease. There is a positive correlation between 
significant obstructive coronary artery disease predicted by Gensini score, 
ACC/AHA score and number of coronary vessel involvement and serum TNF 
alpha and Interleukin 6 level. Between the acute myocardial infarction (complete 
occlusive disease) and unstable angina, chronic stable angina (partial obstructive 
disease) the TNF alpha and Interleukin 6 level is higher in acute myocardial 
infarction patients. This shows that TNF alpha and Interleukin 6 is a pro-
inflammatory activity. Elevated TNF alpha and Interleukin 6 levels are 
independent of other novel risk factors. This shows TNF alpha and Interleukin 6 
plays a role in atherosclerosis. We also found that higher serum TNF alpha and 
Interleukin 6 level were associated with dyslipidemia, blood pressure and 
angiographic severity of coronary artery disease. 
  These findings are likely due to multiple factors such as increased 
sympathetic activity, enhanced platelet aggregation, increased oxidative stress, or 
endothelial dysfunction effects. 
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CONCLUSIONS 
 
1. There is statistically significant increase in serum TNF alpha and Interleukin 
6 values in patients with CAD. 
2. There is also a positive correlation between BMI and Interleukin 6 which 
indicate proatherogenic, proinflammatory role. 
3. The serum values of TNF alpha and Interleukin 6 positively correlate with 
the angiographic severity of CAD. 
4. Further large studies needed to confirm and to determine the prognostic 
significance.  
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LIMITATIONS OF THE STUDY 
 
Despite the statistically significant results of this study, this study examined 
a small number of patients. Large cohorts are required in local settings to assess the 
relationship of TNF alpha and Interleukin 6 levels with the severity of coronary 
atherosclerosis in local settings. The concentrations of serum TNF alpha and 
Interleukin 6 level vary according to different measuring time.       
 
The coronary angiographic assessment is based upon luminal assessment 
and lacks plaque visualization. Intravascular ultrasound (IVUS) based assessment 
of coronary atherosclerotic burden in correlation with serum TNF alpha and 
Interleukin 6 levels may be an area of interest for future investigation. 
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1 Aanbalagan 65 1 1 CAD 53 152 22.94 1 32 35 0.91 180 100 83 120 24 79 17 25 30.6 4.2 N N,R90 99 99 64 12 
2 Bashir 44 1 1 AWMI 57 150 25.33 3 36 35 1.02 130 99 61 142 30 100 12 38 27.5 3.3 N 50-70 70 30 18 5 
3 Elumalai 49 1 3 CAD 62 172 20.96 1 30 34 0.88 110 100 135 165 34 104 27 31 13.1 4.1 N 99 N 99 40 8 
4 Aruldoss 59 1 4 CAD 66 171 22.57 1 39 36 1.08 120 80 107 165 33 111 21 32 26.8 5.2 70 N 70 90 47.5 8 
5 Bakthavatchalam 37 1 4 CAD 67 169 23.46 3 36 35 1.03 170 110 271 224 49 121 54 26 35.6 9.8 N 
30-
50,30 70,50 N 9 7 
6 Arokiyaraj 57 1 2 AIWMI 53 158 21.23 1 34 37 0.92 160 100 145 224 50 145 29 56 30.7 6.8 N 30 30 30 12 3 
7 dayalan 57 1 2 IWMI 66 170 22.84 1 38 39 0.97 110 70 109 142 28 94 20 31 26.2 6.2 20 N 95 90 36 13 
8 Indira 51 2 2 CAD 50 166 18.14 5 31 33 0.94 130 100 156 357 46 124 28 14 19.1 4.9 N N N 99 0 0 
9 Gunasekar 45 1 3 IWMI 50 145 23.78 3 31 38 0.82 130 90 138 327 65 234 28 41 31.8 9.8 n n n n 0 0 
10 ganesh 53 1 0 CAD 55 169 19.26 1 33 35 0.94 100 70 67 181 36 132 13 35 20.5 6.6 Nn 50 70 n 12.5 6 
11 faizer ali 48 1 3 RAWMI 54 162 20.58 1 34 35 0.97 140 80 210 216 44 130 42 16 21.5 4.8 N N N N 0 0 
12 ellappan 48 1 0 RIWMI 85 170 29.41 2 37 39 0.95 110 80 160 219 44 143 32 37 49.8 9.8 N 90 N N 20 8 
13 Ekambaram 41 1 3 CAD 89 182 26.87 3 39 42 0.93 100 70 392 203 30 95 78 20 30.5 7.1 N N 90 100 72 12 
14 Dhanasekar 53 1 0 AWMI 70 176 22.60 1 36 38 0.9 160 100 256 242 49 142 51 27 23.2 3.8 n 70 90 n 14 6 
15 Baskaran 23 1 3 AWMI 66 164 24.54 3 33 36 0.92 130 90 165 188 39 116 33 33 27.2 7.4 n n n n 0 0 
16 Arumugam 28 1 0 AWMI 54 153 23.07 3 31 34 0.84 130 80 94 172 36 117 19 25 13.5 5.4 n n 100 50 50 6 
17 arthikani 36 2 0 CAD 55 151 24.12 3 31 34 0.91 140 100 198 247 50 157 40 140 27.8 4.3 n 99 ,50,90 
 
70 19 
18 Antony 59 1 0 AWMI 63 174 20.81 1 37 38 0.98 130 100 157 278 57 190 31 41 13.5 4.8 n 70-90 50=70 70 26 10 
19 Alli 44 2 0 AIWMI 78 172 26.37 3 39 41 0.98 180 120 296 358 46 135 35 38 32.3 3.6 N N N N 0 0 
20 Ahmed basha 40 1 3 CAD 65 167 23.31 3 36 37 0.91 210 140 259 253 51 150 52 23 32.6 8.9 n 90 30 70 14 5 
21 Ahmad Ullakhan 58 1 0 RAWMI 62 165 22.77 1 38 39 0.97 110 80 124 210 38 148 24 21.5 28.6 10.1 N N 30 90 13 5 
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22 Abdhul Razak 45 1 0 AASMI 54 162 20.58 3 32 35 0.91 170 100 195 157 34 84 39 31 19.4 6.7 N 50,70 90 50 19.5 10 
23 abdul 49 1 0 RIWMI 57 160 22.27 1 32 35 0.91 120 80 270 159 32 73 54 36 32.7 9.8 N 70 N N 6 2 
24 Arumugam 44 1 0 AWMI 75 176 24.21 3 42 40 1.05 120 80 191 205 41 126 38 38 30 4.1 N 70 N 99 22 6 
25 Periyasamy 45 1 0 CAD 41 159 16.22 5 28 33 0.85 130 100 78 184 37 131 16 62 23.5 7.8 N 90 N N 24 4 
26 Pasupathi 60 1 3 RVMI 80 160 31.25 2 43 41 0.95 110 70 234 317 63 207 47 34 41.2 38 N 90 99 80 58 19 
27 Panner Selvam 58 1 0 IWMI 56 170 19.38 1 34 36 0.94 140 90 315 245 49 133 63 31 22.4 6.2 N 30-70 90 99 40 13 
29 Pahurdeen 65 1 0 CAD 39 160 15.23 5 29 34 0.85 180 90 128 178 38 114 26 22 17.1 4.9 70 70 70.7 90 40 12 
30 Nagaraj 60 1 0 IWMI 66 180 20.37 1 38 39 0.97 170 120 187 202 40 125 37 34 13 4.2 N N IRR n 33 4 
31 Murugan 44 1 0 AWMI 57 150 25.33 3 36 35 1.02 130 90 61 142 30 100 12 38 27.5 3.3 n 99,70 80 30 29 9 
32 Murali 60 1 0 IWMI 68 170 23.53 3 32 31 1.03 130 90 194 310 62 209 39 25 29.6 9.7 n n n 40 4 1 
33 Vijayan 52 1 0 AWMI 51 174 16.85 5 31 34 0.91 140 90 83 292 58 217 17 39 25.4 10.1 n 99,70 80 30 43 11 
34 Vijayakumari 52 2 0 IWMI 55 180 16.98 5 32 36 0.89 140 9 108 258 45 135 22 47 18.5 5.6 N 40 N 50 4 3 
35 Vijay 60 1 3 CAD 71 153 30.33 4 41 43 0.95 150 90 196 193 39 115 39 20 36.2 7.8 N 70 70 80 16 6 
36 Veeramuthu 50 1 0 AWMI 66 176 21.31 1 35 36 0.97 140 100 156 238 49 157 23 41 29.4 5.6 n 50 n n 6 2 
37 Thulasidoss 67 1 0 AWMI 56 169 19.61 1 36 37 0.97 160 110 88 234 45 171 18 26 25.6 6.8 n 99,100 40 40 66 10 
38 Thangamani 55 1 4 AWMI 49 153 20.93 1 31 37 0.84 140 90 132 155 31 98 26 35 32.1 7.2 30 80 99 99 64 14 
39 Ravichndran 54 1 1 AWMI 62 165 22.77 1 38 39 0.97 110 80 124 210 38 148 24 21.5 28.6 10.1 n 90 40 40 34 8 
40 Tajum Begam 40 2 2 CAD 70 170 24.20 3 36 40 0.19 150 100 147 264 53 182 29 41.5 16.6 5.2 n n n n 0 0 
41 Rathakrishnan 45 1 0 IWMI 76 159 30.06 4 40 44 0.9 150 100 169 222 44 144 34 26 27 4.7 n 70,90 n 99 52 12 
42 Anif 50 1 3 CAD 56 160 21.88 1 35 37 0.95 140 100 390 135 28 129 22 114 19.2 7.1 N 99 N IRR 25 4 
43 allathiya 48 2 0 RAWMI 61 176 19.69 1 33 36 0.92 120 80 399 276 55 141 80 36 24.5 6.1 N 70 N 20 5 3 
44 Kesavan 42 1 0 CAD 59 170 20.42 1 36 37 0.98 140 90 160 138 20 86 32 47 22.9 6.5 N N N N 0 0 
45 Selvaraj 50 1 0 RIWMI 51 157 20.69 1 34 35 0.97 150 100 211 156 32 82 42 45 24.3 5.1 N N N N 0 0 
46 Xavier 58 1 0 CAD 73 173 24.39 3 39 41 0.95 110 70 102 140 28 92 20 244 36.7 8.5 N 50-70 30-50 40 14 6 
47 Stephen 40 1 0 CAD 70 160 27.34 3 39 42 0.93 150 90 215 217 44 130 43 54 41.9 6.8 N 90 70 N 15 6 
48 Shanthi 60 2 0 CAD 50 143 24.45 3 37 34 1.09 130 90 141 240 50 162 28 60 29.6 5.1 N 99 N 100 64 8 
49 Shanmugam 45 1 0 AWMI 63 167 22.59 1 36 37 0.97 170 130 185 190 49 104 37 62 26.6 9.6 N 70 N 50 13 6 
50 Shankar 63 1 0 CAD 57 158 22.83 1 32 36 0.89 140 90 95 147 30 98 19 32 26.7 7.5 n 90 99 20 42 9 
51 S.Rajan 66 1 0 RASMI 55 166 19.96 1 33 37 0.89 110 80 92 212 43 151 18 35 24.1 3.1 n 90 n n 24 4 
52 Ravi 61 1 0 CAD 60 168 21.26 1 35 38 0.92 210 120 129 136 41 71 24 25 19.6 4.6 50 70 70 100 55 16 
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53 Ramu 39 1 0 CAD 86 186 24.86 3 38 40 0.95 100 80 154 196 40 125 31 27 40.2 6.7 N 100 N N 48 4 
54 Santhanam 66 1 0 CAD 54 150 24.00 3 36 40 0.9 130 90 248 321 45 168 45 57.6 23.2 7.8 50 99 90 70 47 16 
55 Ravindran 48 1 0 CAD 72 171 24.62 3 37 41 0.9 110 70 192 167 34 95 38 72 48.6 7.1 N N N 30 2 1 
56 Mary 43 2 0 CAD 78 162 29.72 2 39 42 0.93 160 100 80 152 30 106 16 38.6 39.8 10.6 n 50,50,50 30 n 11.5 4 
57 Jayaraman 45 1 1 IWMI 52 165 19.10 1 32 33 0.97 130 80 207 253 51 160 42 29 14.2 3.2 n 60 100 90 74 10 
58 Kanniyammal 53 2 4 CAD 64 139 33.10 2 40 41 0.98 150 100 195 173 37 97 39 102 35.6 7.2 40 80 N N 26 6 
59 KUMAR 47 1 2 CAD 60 165 22.00 1 35 36 0.97 130 80 249 176 36 90 50 65 19.1 7.1 n n n n 0 0 
60 Lalitha 48 2 2 CAD 70 165 25.71 3 40 44 0.91 210 140 259 253 51 150 52 23 32.6 8.9 30 70,99 50 20 51 10 
61 Lalitha 60 2 1 CAD 60 151 26.30 3 40 39 1.03 160 70 243 177 36 92 49 48 16.1 6.1 N 100 N 70 53 6 
62 Kousalya 41 2 3 IWMI 67 169 23.46 3 36 35 1.03 170 110 271 224 49 121 54 26 35.6 9.8 20 99 50,50 30 60 10 
63 Kamakshi 47 2 0 AWMI 50 169 17.51 5 35 40 0.88 110 90 110 198 40 136 22 66 23.1 6.1 n 100 90 n 72 8 
64 Ibrahim 46 1 2 AWMI 65 166 23.60 3 36 37 0.97 140 100 193 134 43.5 68 39 68 15.9 3.2 N 50 90 N 11.5 6 
65 gopi 47 1 4 CAD 62 153 26.49 3 39 40 0.97 140 90 253 230 48 131 51 68 29.5 5.1 n n n n 0 0 
66 Ganesan 49 1 1 CAD 56 159 22.10 1 33 36 0.92 100 70 115 171 36 112 23 16.5 18.6 4.2 N 70 N N 7 2 
67 Eswaran 58 1 4 CAD 70 157 28.30 2 38 44 0.86 140 90 171 132 28 70 34 26 35.6 7.1 N N N N 0 0 
68 Balaraman 54 1 3 ASMI 82 174 27.10 3 42 43 0.97 130 80 157 269 55 183 31 36.5 29.6 7.5 N N N N 0 0 
69 Ramaiah 60 1 3 CAD 51 155 21.23 1 29 33 0.87 110 70 124 108 25 58 25 24 20.2 8.1 n 99 n n 40 4 
70 Vijaykumar 60 1 4 IWMI 67 152 29.00 2 42 46 0.91 160 90 168 177 34 110 33 65 40.2 7.8 30 90 99 100 117 13 
71 Vijayakumar 48 1 4 AWMI 55 167 19.70 1 34 35 0.97 160 80 156 106 22 53 31 54.5 12.6 6.2 n 50,70 50,70 n 20 8 
72 Venkatachalapat 45 1 2 IWMI 61 180 18.83 1 36 38 0.95 160 100 118 185 37 124 24 63 21.1 6.2 n n 70,70 100 60 10 
73 Varadan 49 1 3 IWMI 68 160 26.00 3 39 40 0.98 110 80 207 234 48 145 41 20 18.6 5.1 n 90 100 n 72 8 
74 Thiagaraj 60 1 1 CAD 50 153 21.40 1 30 33 0.9 140 110 110 142 30 90 22 23 21.1 5.2 n 100 99 70 60 14 
75 Subramani 60 1 0 AWMI 58 164 21.56 1 37 36 1.03 150 90 111 180 36 123 21 38 30.2 8.2 n 70 n 70 28 6 
76 Sumathy 42 2 3 CAD 68 157 27.60 2 38 43 0.88 130 100 72 163 33 116 14 47.6 22.6 4.1 n 70 n 70 20 6 
77 Ramu 57 1 0 CAD 50 145 23.78 3 31 38 0.82 130 90 138 327 65 234 28 41 31.8 9.8 n n n n 0 0 
78 Raji 32 1 0 ASMI 80 160 31.23 3 40 41 
 
120 80 145 271 46 196 29 49 19.2 8.2 N 90 N N 20 4 
79 Hussain 55 1 3 CAD 70 167 25.10 3 38 36 1.06 100 70 364 240 48 119 73 4 36.7 9.9 50 70,70 70 75 80 20 
80 Nagaraj 38 1 2 UA 83 171 28.42 2 41 47 0.8 120 80 120 210 26 160 24 31 37.6 7.4 N N N N 0 0 
81 James 52 1 0 CAD 65 167 23.30 1 30 36 0.8 150 100 150 258 32 120 20 14 17.5 3.6 N 60,99 N 30 36 9 
82 Joseph 50 1 0 AASMI 58 169 20.28 1 32 35 0.8 110 70 148 270 37 203 30 41 15.8 6.7 N 50,100 N N 51 5 
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83 Baskaran 67 1 2 ASMI 72 174 23.70 1 38 39 0.9 130 100 167 318 40 244 34 35 19.8 5.2 N 90,99 N N 29 8 
84 Bagvathi 55 1 0 CAD 75 162 27.98 2 41 39 1 150 90 130 158 30 102 26 16 28.6 3.9 N 90 70 90 15 6 
85 Devi Bai 45 2 0 ASMI 60 172 23.47 1 33 36 0.9 120 80 150 187 35 125 30 37 25.4 4.9 N 50,70 40,40 90 35 15 
86 Duraisamy 37 1 0 AWMI 72 164 26.00 2 39 40 0.9 130 80 325 393 42 286 65 20 20.9 3.1 N N N N 0 0 
87 
Mohammed 
Ghouse 54 1 0 AWMI 60 161 23.00 1 37 34 1.7 110 90 174 210 50 126 34 27 17.8 3.4 N 90 40 N 14 5 
88 Pappammal 47 2 0 AWMI 71 155 29.58 2 37 45 0.8 120 80 120 178 32 122 24 33 35.5 4.8 N 99 60,50 40 20 7 
89 Rajendran 50 1 0 CAD 76 167 27.21 2 39 39 1 110 90 185 248 49 162 37 25 28.6 7.8 N 50 80,40 N 23 8 
90 Sheik Mohideen 52 1 3 CAD 58 165 21.32 1 32 33 0.9 140 100 110 270 40 208 22 140 20.8 6.1 N 70 80 30 11 5 
91 Sugumaran 38 1 0 CAD 77 163 28.95 2 38 42 0.9 100 70 125 215 50 140 25 41 32.7 6.9 N 90 70 90 20 10 
92 Vijaya 51 2 0 CAD 81 167 29.03 2 37 38 
 
160 100 140 214 46 140 28 38 30.6 7.3 A N N 99, 18 6 
93 Velu 51 1 0 CAD 75 151 26.60 2 39 40 0.9 130 90 165 272 48 191 33 23 17.4 7.7 N 30,50 N 
 
3 2 
94 Venkatesh 50 1 4 CAD 64 152 27.00 2 33 38 0.8 140 80 130 217 41 150 26 21 23.1 6.7 N N N 99 80 8 
95 Velu 33 1 3 CAD 70 168 24.82 1 31 34 0.9 120 80 155 193 42 118 31 31 25.7 5.3 N N N 30 2 2 
96 Ramu 65 1 3 CAD 60 166 21.76 1 35 34 1.2 120 90 200 226 52 134 40 36 27.8 3.7 N 99 N N 42 6 
97 Sakunthala 38 2 0 CAD 56 146 26.29 2 38 43 0.9 120 80 164 264 47 232 32 38 29.3 5.9 N 100,9O N N 51 6 
98 Pandiyan 37 1 0 CADi 62 149 27.93 2 43 40 1.7 130 80 181 328 49 243 36 62 30.2 7.9 n 90 50 20 30 6 
99 Paramisivam 45 1 0 CAD 75 175 24.50 1 42 40 1.5 120 90 183 189 48 106 37 34 19.5 6.2 N 70 90 70 24.5 11 
100 Rajendran 31 1 3 CAD 56 168 19.86 1 36 39 0.9 160 110 142 186 42 116 28 31 24.6 6.7 N 90 N N 12 4 
101 Rajendran 58 1 3 CAD 68 162 25.95 2 35 33 1.5 130 70 140 278 40 210 28 22 27.8 5.9 N N 90 50 20 5 
102 Mohammed 36 1 0 CAD 
   
1 
   
120 80 
     
34 20.2 7.2 N N N NN 0 0 
103 Gopal 41 1 3 CAD 80 176 25.81 2 33 41 0.8 150 120 141 260 31 135 32 27 30.7 7.7 n 90,70 n n 28 6 
104 Kasinathan 54 1 3 CAD 66 165 24.26 1 40 43 0.9 140 100 168 235 50 151 34 57 36.2 7.5 N 100 N 
50-
70 52 6 
105 Krishnaveni 42 2 0 RIWMI 76 168 26.95 2 42 41 1.2 160 120 116 325 48 254 23 72 32.8 8.1 N N N 90 8 6 
106 Kumaran 52 1 0 IWMI 70 158 27.89 2 45 42 1.6 130 80 186 289 46 203 37 38 29.6 8.3 N 70 N 90 14 6 
107 lelienraj 55 1 3 CAD 80 171 27.40 2 38 38 1 120 80 145 279 41 209 39 29 21.7 7.1 N 90,70 50,70 N 34 10 
108 Masthan 65 1 3 CAD 80 171 27.40 2 38 38 1 120 80 
     
102 31.7 7.1 N N 30 N 3 1 
109 Pangathachan 60 1 3 CAD 54 168 19.15 1 38 39 1.2 110 80 165 286 52 201 33 65 28.7 7.2 30 99 70,90 99 60 19 
110 Raju 54 1 1 CAD 75 158 30.00 2 42 41 1.2 120 80 155 165 36 108 31 23 32.6 3.9 A 90 N 20 7 4 
111 Rajendran 48 1 0  AWMI 58 146 27.03 2 35 38 0.9 120 80 140 198 42 128 28 48 26.7 5.8 N N N N 0 0 
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112 Pazhani 35 1 0 CAD 55 166 19.93 1 34 38 0.8 120 80 186 312 48 227 37 26 19.8 7.8 N N N N 0 0 
113 RAMESH 42 1 3 CAD 60 145 28.57 2 40 38 1.5 130 90 182 261 47 178 36 66 28.1 4.7 N N N N 0 0 
114 Subramani 62 1 0 CAD 58 149 26.13 2 37 39 0.9 140 80 136 265 36 202 27 68 31.3 7 50 99,99,70 99 70,70 82 23 
115 Srinivasan 50 1 0 CAD 62 163 23.31 1 41 45 0.9 110 70 145 300 49 222 29 68.5 19.7 8.2 N 
50,70-
90 N N 23 8 
116 Shanthi 60 2 0 RIWMI 65 149 29.29 2 40 38 1.4 150 110 120 174 40 114 24 16 32.8 7.8 N 90 90,90 N 9.5 4 
117 Shahul 58 1 0 CAD 66 161 25.48 2 39 40 0.9 110 80 152 279 48 201 30 26 26.1 6.1 N 30 N 40 6.5 2 
118 Santhosh 42 1 0 CAD 60 146 20.17 1 41 43 0.9 140 90 170 258 47 177 34 36 16.2 3.2 N 99 90 30 34 9 
119 Murugesan 40 1 3 CAD 74 157 30.08 2 42 44 0.9 130 100 182 321 53 232 36 24 29.1 8.3 N N 30 60,80 23 10 
120 Palani 59 1 0 AIWMI 55 159 21.73 1 39 40 0.9 120 90 189 311 53 220 38 65 20.8 4.8 N 99,100 90 N 84 12 
121 Natarajan 52 1 1 AASMI 55 156 22.63 1 41 40 1.2 110 80 152 242 49 163 30 54 19.8 5 N 70 70 N 12 4 
122 Naveesammal 52 2 0 IWMI 65 166 23.55 1 39 42 0.8 140 120 131 248 43 179 26 46 22.3 3 N N N N 0 0 
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                                                          PROFORMA    
 
Name : 
 
Age :  
 
Sex :  
 
Address :   
 
CD No. : 
 
SYMPTOMS : 
No symptoms: 
Chest pain: 
SOB Class: 
Palpitations 
 
 
Risk Factors 
Hypertension                                            Diabetes Mellitus 
                                         
Smoking                                                    Family History 
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Menopause 
 
 
 
 
Past History : 
 
 
 
 
Treatment History 
 
 
 
Physical Examination 
 
1. General Examination 
 
 
2. Vital Signs 
 
B.P 
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Pulse 
 
Respiration                                         JVP Height cm Waveform 
 
3. Systemic Examination 
 
 
CVS 
 
Inspection / Palpation 
 
Apex                                                                         Parasternal Heave 
 
Palpable Sounds                                                     Thrills 
 
Auscultation 
 
 S1             S2                                                       Murmurs 
 
 
 
Extra Heart Sounds 
 
 
Other System 
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RS:                                PA:                                                      CNS : 
 
 
 
ECG: 
 
 
ECHO : 
 
SERUM TNF-ALPHA  :                     pg/ml 
 
SERUM IL-6 :                                    pg/ml 
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   CORONARY ANGIOGRAM : 
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PATIENT CONSENT FORM 
STUDY TITLE : 
“ CORRELATION OF SERUM TNF- ALPHA AND IL-6 LEVEL  WITH 
ANGIOGRAPHIC SEVERITY OF CORONARY ARTERY DISEASE” 
 Patient may check () these boxes. 
PARTICIPANT  NAME :                                           DATE:                           
 AGE:              SEX:                                     I.P.NO. : 
The details of the study have been provided to me in writing and explained to me in my own 
language. 
I confirm that I have understood the purpose of  the above study. I have the 
opportunity to ask the question and all my questions and doubts have been 
answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal rights being 
affected. 
I understand that investigator, the institution, regulatory authorities and the ethical 
committee will not need my permission to look at my health records both in 
respect to the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I understand that my identity will 
not be revealed in any information released to third parties or  published, unless as 
required under the law. I agree not to restrict the use of any data or results that 
arise from this study.  
 I hereby consent to,undergo complete physical examination ,and diagnostic tests 
including hematological,biochemical,radiological and urine examinations 
 
I have been given an information sheet giving details of the study . 
I hereby consent to participate in the above study  
                                                       
 
        Signature of the Participant 
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Information to Participants 
 
Title: CORRELATION OF SERUM TNF- ALPHA AND IL-6 LEVEL  WITH ANGIOGRAPHIC SEVERITY OF 
CORONARY ARTERY DISEASE 
Principal Investigator:  
Co-Investigator(if any): 
Name of Participant: 
Site :   RGGGH& MMC, Chennai 
You are invited to take part in this research/ study/procedures/tests. The information in this document is 
meant to help you decide whether or not to take part. Please feel free to ask if you have any queries or 
concerns. 
What is the purpose of research? 
Several pro-inflammatory cytokines, including interleukin-1, IL-6, IL-8, tumor necrosis factor-
alpha, as well as anti-inflammatory cytokines IL-1 receptor antagonist and IL-10, have been 
identified as part of the inflammatory process of atherosclerosis.Serum levels may be elevated in 
patients with coronary artery disease. We therefore evaluated the relationship between the level 
of inflammatory cytokines and the extent and severity of CAD.We have obtained permission from 
the Institutional Ethics Committee.  
The study design 
 It is a Prospective observational study  
Study Procedures 
 The study involves evaluation of serum TNF- alpha and IL-6 level  with angiographic severity of 
coronary artery disease. 
 
Confidentiality of the information obtained from you 
 You have the right to confidentiality regarding the privacy of your medical information (personal 
details, results of physical examinations, investigations, and your medical history). By signing this 
document, you will be allowing the research team investigators, other study personnel, sponsors, 
Institutional Ethics Committee and any person or agency required by law like the Drug Controller General 
of India to view your data, if required. 
The information from this study, if published in scientific journals or presented at scientific meetings,  
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will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or your relationship 
with the investigator or the institution. You will be taken care of  and you will not loose any benefits to 
which you are entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw from this study at 
any time during the course of the study without giving any reasons. However, it is advisable that you talk 
to the research team prior to stopping the treatment/discontinuing of procedures etc. 
 
 
Signature of Investigator                                                                      Signature of Participant   
 
date                                                                                                      date   
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ACRONYMS & ABBREVIATIONS 
 
TNF     - Tumor necrosis Factor 
IL -6     - Interleukin 6 
CAD    - Coronary Artery Disease 
CVD    - Cardiovascular Study 
LMCA   - Left Main Coronary Artery 
LAD    - Left Anterior Descending Artery 
LCX    - Left Circumflex Artery 
RCA    - Right Coronary Artery 
OM    - Obtuse Marginal Artery 
PDA    - Posterior Descending Artery 
PLB    - Posterolateral Branch 
S D    - Standard deviation 
ANOVA   - Analysis of Variance 
ACC    - American College of Cardiology 
AHA    - American Heart Association 
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